BociMed is a biotechnology and healthcare startup, founded in 2012 with a focus on drug research and development as well as clinical research. The company's slogan "Delivering Excellence in Drug Research and Development with Industry-Leading Expertise" underscores its commitment to providing premium R&D and outsourcing services for drug discovery, preclinical pharmaceutical research, and development, as well as clinical I-IV trials and registration. BociMed, originally known as Shanghai Maibo Pharmaceutical Technology Co., Ltd., was registered in Jinshan Petrochemical Zone and has since evolved from primarily engaging in raw material sales, drug import registration, and regional cooperation development in China to establishing itself as a high-tech enterprise specializing in drug R&D technical services.
In 2023, the company secured a CNY100.00M Series B investment from Guoxin Investment. Notably, BociMed has garnered recognition as a Shanghai High-tech Enterprise, Shanghai Credit Creation Enterprise, and Shanghai Small and Medium Enterprise Innovation Undertaking Enterprise, demonstrating its commitment to innovation and development within the industry. While the company's headquarters location is not specified, its significant investment and recognition within the industry underscore its growth potential and the confidence of investors in its innovative approach to drug research and development.
